Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus salivarius WB21 + xylitol
- Development stage
- Unknown
- Lead developer
- Wakamoto
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus salivarius WB21 is a probiotic bacterial strain formulated with xylitol for the treatment of halitosis (bad breath). Investigated for this indication by the University of Nove de Julho (UNINOVE) and commercially available in Japan as Minna No Zendamakin WB21 by Wakamoto Pharmaceutical, it works by modulating the oral microbiota. The probiotic reduces the population of proteolytic bacteria and volatile sulfur compound (VSC)-producing bacteria on the tongue coating, which are the primary biological drivers of oral malodor. In clinical research, the strain is typically administered in capsules or tablets to suppress the growth of anaerobic bacteria that degrade proteins into foul-smelling sulfur gases.
- Brand names
- Minna No Zendamakin WB21 Tablet
- Other names
- Lactobacillus salivarius WB21WB21 probioticWB-21 probioticWB 21 probiotic
Beyond the preview
Go deeper on Lactobacillus salivarius WB21 + xylitol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus salivarius WB21 + xylitol.